Nuevo Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -26.95%
- Profit Growth -45.79%
- Ebitda -243.06%
- Net Worth 9.94%
- Total Assets 16.21%
About Nuevo Therapeutics
Nuevo Therapeutics Private Limited (NTPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 January 2013 and has a history of 12 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mitra Puchhalapalli, Geetha Channa, and Priyatham Chennareddy serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232TG2013PTC085338
- Company No.
085338
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Pharma
Nuevo Therapeutics Private Limited
Explore comprehensive data for Nuevo Therapeutics Private Limited, including financials, compliance details, shareholding patterns, and litigation history.
Who are the key members and board of directors at Nuevo Therapeutics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mitra Puchhalapalli  | Director | 10-Jan-2013 | Current |
| Geetha Channa | Director | 10-Jan-2013 | Current |
| Priyatham Chennareddy | Director | 10-Jan-2013 | Current |
Financial Performance of Nuevo Therapeutics.
Nuevo Therapeutics Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 26.95% decrease. The company also saw a substantial fall in profitability, with a 45.79% decrease in profit. The company's net worth moved up by a moderate rise of 9.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nuevo Therapeutics?
In 2021, Nuevo Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Genova Biotechniques Private LimitedMitra Puchhalapalli is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nuevo Therapeutics?
Unlock and access historical data on people associated with Nuevo Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nuevo Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nuevo Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Latest Updates, News, and FAQs on Nuevo Therapeutics
Recent activity within the organization
- Annual General Meeting
Nuevo Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
- Balance Sheet
Nuevo Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
- Director Appointment
Mitra Puchhalapalli was appointed as a Director was appointed as a Director on 10 Jan 2013 & has been associated with this company since 12 years 4 months .
- Director Appointment
Geetha Reddy Channa was appointed as a Director was appointed as a Director on 10 Jan 2013 & has been associated with this company since 12 years 4 months .
- Director Appointment
Priyatham Reddy Chennareddy was appointed as a Director was appointed as a Director on 10 Jan 2013 & has been associated with this company since 12 years 4 months .
- Company Incorporation
Nuevo Therapeutics Private Limited was registered on 10 Jan 2013 with Roc Hyderabad & aged 12 years 4 months as per MCA records.
Frequently asked questions
What is the Incorporation or founding date of Nuevo Therapeutics Private Limited?
Nuevo Therapeutics Private Limited was incorporated on 10 Jan 2013.
What is authorized share capital and paid-up capital of Nuevo Therapeutics Private Limited?
The authorized share capital of Nuevo Therapeutics Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.
Who are the current board members & directors of Nuevo Therapeutics Private Limited?
Currently 3 directors are associated with Nuevo Therapeutics Private Limited.
- Mitra Puchhalapalli
- Geetha Reddy Channa
- Priyatham Reddy Chennareddy
What is the registered address of Nuevo Therapeutics Private Limited?
As per Ministry of Corporate Affairs (Mca), the registered address of Nuevo Therapeutics Private Limited is M. No. 8-2-502/1/A Jivi Towers Road 7, Banjara Hills India, Hyderabad, Telangana, 500034.
What is the corporate identification number (CIN) and company number of Nuevo Therapeutics Private Limited?
The corporate identification number (CIN) of Nuevo Therapeutics Private Limited is U24232TG2013PTC085338 and the company number is 085338 as per Ministry of Corporate Affairs (MCA).
What is the official website of Nuevo Therapeutics Private Limited?
The Official website of Nuevo Therapeutics Private Limited is https://www.nuevo.co.in
What has been the recent revenue trend for Nuevo Therapeutics Private Limited?
According to the financial reports for the fiscal year 2022, the revenue trend for Nuevo Therapeutics Private Limited has fallen by -26.95%.
What change has been observed in the net worth of Nuevo Therapeutics Private Limited, and by what percentage?
The financial reports for the fiscal year 2022 indicates that The net worth of Nuevo Therapeutics Private Limited has experienced an upsurge of 9.94%.
When was the last Balance Sheet of Nuevo Therapeutics Private Limited filed with the ROC?
The most recent Balance Sheet for Nuevo Therapeutics Private Limited was filed with the ROC on 31 Mar 2024.
Unlock Business Insights – Explore Instantly!
Search company & director profiles for free and gain access to critical business data.
- 3.1M+ Companies
- 15M+ Legal Cases
- 525K+ Credit Ratings
- 5.8M+ Directors & KMP
- 750K+ Regulatory Alerts
- 1.1M+ Companies' Financial Records